Plain-English translation of NCT04919512 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested , a medication delivered directly into the bladder, combined with an immunotherapy drug called , compared to alone. The study involved people with muscle-invasive bladder cancer who were scheduled to have their bladder surgically removed and who were unable or unwilling to receive standard chemotherapy. Researchers examined whether these treatments could help shrink tumors and improve outcomes before surgery.
Many patients with muscle-invasive bladder cancer cannot tolerate or choose not to receive standard chemotherapy before surgery. This trial was designed to see whether this new medication and immunotherapy combination could offer an effective alternative to help control the cancer and improve survival.
Participants were divided into two groups: some received (delivered directly into the bladder) plus an immunotherapy injection, while others received only the immunotherapy injection. The trial lasted up to 2.5 years total and included a screening phase, a treatment phase leading up to bladder removal surgery, and a follow-up phase. Participants underwent regular clinic visits for assessments, imaging scans, and blood tests to monitor how well the treatment was working and how their body was responding.
AI-generated summary from trial data · Sep 21, 2026 · Not medical advice
United States